Pharmaceutical care of a child with high-risk neuroblastoma using naxitamab
10.12173/j.issn.1005-0698.202502044
- VernacularTitle:1例高危神经母细胞瘤患儿使用那西妥单抗的药学监护
- Author:
Yin CHEN
1
;
Xin LIU
;
Liting YU
;
Min ZHANG
Author Information
1. 上海交通大学医学院附属上海儿童医学中心药剂科(上海 200127)
- Publication Type:Journal Article
- Keywords:
Neuroblastoma;
Naxitamab;
Adverse drug reaction;
Pharmaceutical care;
Pain
- From:
Chinese Journal of Pharmacoepidemiology
2025;34(5):595-599
- CountryChina
- Language:Chinese
-
Abstract:
This article reported the clinical pharmacist's involvement in the treatment of a high-risk neuroblastoma pediatric patient with naxitamab and the implementation of individualized medication monitoring.Upon admission,the clinical pharmacist collaborated with the physician to develop a dosing regimen and an allergy-prevention plan for naxitamab.On the day of administration,the pediatric patient experienced an infusion-related reaction.After evaluating by the physician and clinical pharmacist,the pediatric patient was administed albumin for volume expansion,electrolyte supplementation,vasopressor support,and mechanical ventilation,while temporarily suspending naxitamab infusion.Concurrent anti-inflammatory and infection-prevention therapies led to the pediatric patient's improvement,allowing the completion of the remaining three naxitamab infusions.The clinical pharmacist provided pharmaceutical recommendations for infusion-related pain,rash,and hypotension,which were adopted by the physician.As one of the earliest cases of naxitamab use in China,this case highlighted the role of clinical pharmacists in pharmaceutical care for patient with complex conditions,particularly in optimizing treatment plans and ensuring medication safety,offering practical experience and reference for the rational use of naxitamab in pediatric patients.
